Stock listing

NASDAQ:IVVD Invivyd, Inc. Stock

Home listing (NASDAQ) of Invivyd, Inc.

Follow Invivyd, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IVVD

$0.608 USD -0.038 (-5.9%)

Close on Oct 14, 2026

Invivyd, Inc. logo
Ticker
NASDAQ:IVVD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Invivyd (NASDAQ:IVVD) Q1 2026 Earnings Call

    Thu, May 14, 2026 · 8:30 AM ET

    Watch Transcript

  • Invivyd (NASDAQ:IVVD) Q4 2025 Earnings Call

    Thu, Mar 05, 2026 · 8:30 AM ET

    Watch Transcript

  • Invivyd (NASDAQ:IVVD) Q3 2025 Earnings Call

    Thu, Nov 06, 2025 · 8:30 AM ET

    Watch Transcript

Latest news

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 5, 2026

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Sep 29, 2026

Invivyd to Participate in Upcoming September Investor Conferences

Sep 8, 2026

Invivyd Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

Sep 4, 2026

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Sep 1, 2026

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 13, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 4, 2026

Aug 5, 2026

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Jul 6, 2026

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Jun 16, 2026

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Adminis...

Jun 9, 2026

All Invivyd, Inc. news

Decks

Invivyd, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
38 in the last 12 months · 135 in all · newest Oct 5, 2026 · oldest 2022
Calls
12 calls with a replay · 12 with a transcript · latest May 14, 2026
Decks
29 decks · latest Sep 29, 2026

Where Invivyd, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IVVD · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IVVDBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Invivyd, Inc.